Imagine being familiar with a drug as a painkiller all your life, and then getting to know that the drug used by millions is not even an effective painkiller. That’s not all, that same drug also ends up raising the risk of heart disease in users!
A new medical analysis is sparking alarm: a painkiller used by millions may do very little to ease chronic pain — and worse, it might double the risk of heart problems. The study focused on tramadol, a prescription opioid often considered safer than stronger alternatives.
What does the study say
Across the United States, 51.6 million adults — roughly 1 in 5 — live with chronic pain, according to the Centers for Disease Control and Prevention. For 17.1 million of them, the agony disrupts both their work and daily activities.
Now, a recent systematic review and meta-analysis in
BMJ Evidence-Based Medicine has placed tramadol — one of the most widely prescribed opioids for moderate to severe pain — under new scrutiny. According to researchers, tramadol’s pain-relieving effects in chronic conditions are modest at best, but its dangers could be far greater than once thought – as its use appears associated with a roughly doubling of serious adverse events, particularly cardiovascular risks. This finding raises serious concerns about how we manage pain — especially long-term — and whether risks have been underestimated.
The team behind the review evaluated nineteen randomized clinical trials involving 6,506 patients who had chronic pain from various causes — including osteoarthritis, neuropathic pain, lower back pain, and fibromyalgia. The trials compared tramadol to a placebo, allowing the researchers to isolate the drug’s true impact beyond expectations.
What are the key findings?
To put it in simpler terms: limited efficacy, with surging risks
Weak pain relief: While some improvements in pain were observed, the magnitude was small and fell below the threshold of what is usually considered clinically meaningful. In simpler terms, many patients might barely feel a difference.
Double risk of serious adverse events: Users of tramadol showed about twice the likelihood of suffering serious complications compared to placebo groups. Among these, cardiac events — such as chest pain, coronary artery disease, and heart failure — stood out.
Other side effects: Milder but common adverse effects also appeared more frequently in tramadol users — nausea, dizziness, constipation, and sedation.
However, there are some notable limitations regarding the data considered for the study as well. The authors revealed that any of the trials had risk of bias, were short in duration (weeks to a few months), and might understate real harms over longer use. Hence, they proposed that their findings could actually underestimate the dangers.
This review challenges long-held beliefs that tramadol is a relatively safer opioid alternative, especially when used for chronic pain.
Why these findings matter
Well, for starters, finding out about the hidden dangers of a well-known and widely used prescription opioid is quite unnerving, as it makes you question all your healthcare choices. Second, Tramadol has often been viewed as a middle ground — more potent than over-the-counter pain relievers but with lower addiction or side-effect risk than classic strong opioids. Clinicians sometimes turn to it when non-opioid treatments fail. So, as this new evidence forces a reappraisal, several doctors and patients have to rethink their choice of opioids. What’s more? Chronic pain affects tens of millions globally, and continuous analgesic therapy is common. If many patients receive tramadol under the assumption of acceptable safety, the possibility of elevated heart risk is deeply concerning. The results also resonate with broader findings that many commonly used pain medications (especially NSAIDs) carry cardiovascular risks when used long-term.
What should patients and doctors do?
First and foremost, reassess the use of tramadol, especially for long-term pain. Patients currently taking it should not stop abruptly but should consult a health provider to weigh risks and benefits. Consider non-opioid or non-pharmacological treatments — physical therapy, exercise, cognitive-behavioral therapy, heat/cold, etc. A multimodal approach often yields better outcomes with lower risk.
In case one has to stick to tramadol, it’s recommended to use the lowest effective dose for the shortest duration possible if medications are needed. Additionally, monitor heart health and risk factors closely, particularly in patients with any cardiovascular history.
Finally, stay updated. Further high-quality trials are needed to confirm these findings, refine patient selection, and guide safer prescribing practices.
Follow Us On Social Media